RUDACURE

New Drug Candidate for Dry Eye syndrome

RCI 001

RCI001

Candidate substance for dry eye treatment with strong anti-inflammatory action

▪ Patents for domestic use 10-1816277, U.S. patent application
10-675294

▪ Domestic technology transfer: Hallym Pharmaceutical Co., Ltd.

▪ Overseas L/O goals after Phase 2 clinical trials

▪ 1st domestic clinical trial: 2022 3Q

▪ US FDA Phase 2: 2022 4Q

{"google":["Noto Sans","Poppins"],"custom":["Noto Sans KR","Nanum Square","Nanum Barun Gothic","Jeju Gothic"]}

{"google":["Noto Sans","Poppins"],"custom":["Nanum Square","Nanum Barun Gothic","Noto Sans KR","Jeju Gothic"]}

Company Name RudaCure Co., Ltd ｜ CEO Yong Ho Kim ｜ CPO Seunghoon Kim
Location
HQ R316, InstarⅠ, 204, Convensia-daero, Yeonsu-gu, Incheon, Republic of Korea
Research Institute R302, BRC1, 9, Songdomirae-ro, Yeonsu-gu, Incheon, Republic of Korea
Seoul Office R1001, 145, Gasan digital 1-ro, Geumcheon-gu, Seoul, Republic of Korea
US Office 40W, 37th St. Suite 801 New York, NY 10018
Corportate registration number 548-86-00995

{"google":[],"custom":["Noto Sans KR","Jeju Gothic"]}